Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Chronic Low Back Pain
NCT00246155Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jan 2005
- Primary completion
- Jul 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abobotulinumtoxinA in chronic low back pain (CLBP), sponsored by Ipsen. Primary endpoints: Pain reduction as assessed by the mean Visual Analogue Scale at 3 months, Oswestry Low Back Pain Questionnaire at 3 months and 1 more. Started Jan 2005; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT00246155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246155.